Payment overview · 2025
General Payments
$74.64
2 reported records · 2 companies
Healthcare provider profile · identity verified
Angel E Michel, MD
Allopathic & Osteopathic Physicians|General Practice · PONCE, PR · NPI 1235281346
Verified facts
What the public records show
CMS Open Payments records show Angel E Michel, MD received $74.64 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 68.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.30 | 68.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.34 | 31.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $74.64 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
45 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 586 | 96 |
| Losartan Potassium | Losartan Potassium | 462 | 85 |
| Simvastatin | Simvastatin | 454 | 85 |
| Gabapentin | Gabapentin | 403 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 53 |
| Lisinopril | Lisinopril | 382 | 67 |
| Metformin Hcl | Metformin Hcl | 376 | 70 |
| Furosemide | Furosemide | 371 | 61 |
| Omeprazole | Omeprazole | 354 | 49 |
| Famotidine | Famotidine | 332 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 47 |
| Buspirone Hcl | Buspirone Hcl | 235 | 45 |
| Temazepam | Temazepam | 228 | 37 |
| Sertraline Hcl | Sertraline Hcl | 227 | 47 |
| Donepezil Hcl | Donepezil Hcl | 226 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 37 |
| Levetiracetam | Levetiracetam | 203 | 27 |
| Trazodone Hcl | Trazodone Hcl | 188 | 40 |
| Carvedilol | Carvedilol | 182 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 23 |
| Clonazepam | Clonazepam | 165 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 155 | 26 |
| Risperidone | Risperidone | 149 | 25 |
| Synthroid | Levothyroxine Sodium | 138 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 16 |
| Meloxicam | Meloxicam | 120 | 19 |
| Finasteride | Finasteride | 119 | 16 |
| Memantine Hcl | Memantine Hcl | 119 | 21 |
| Glimepiride | Glimepiride | 110 | 20 |
| Lorazepam | Lorazepam | 107 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 104 | 20 |
| Baclofen | Baclofen | 102 | 24 |
| Irbesartan | Irbesartan | 84 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 84 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 41 |
| Eliquis | Apixaban | 81 | 12 |
| Montelukast Sodium | Montelukast Sodium | 80 | suppressed |
| Nifedipine Er | Nifedipine | 77 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 13 |
| Enalapril Maleate | Enalapril Maleate | 73 | 11 |
| Chlorthalidone | Chlorthalidone | 68 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 68 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 67 | 18 |
| Glipizide | Glipizide | 65 | 14 |
| Atenolol | Atenolol | 64 | 11 |
| Naproxen | Naproxen | 58 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Ssd | Silver Sulfadiazine | 57 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Humalog | Insulin Lispro | 49 | 12 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 45 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 42 | 17 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Nabumetone | Nabumetone | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Permethrin | Permethrin | 31 | 23 |
| Azithromycin | Azithromycin | 30 | 23 |
| Insulin Lispro | Insulin Lispro | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 29 | 15 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Ramipril | Ramipril | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Desonide | Desonide | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Estazolam | Estazolam | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74.64 · 2 records | GlaxoSmithKline, LLC. | PAXLOVID | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error